Clinical Trials

Overview

About this study

The purpose of this study is to evaluate a serum IgE hemp antibody immunoassay for use in the evaluation of allergies to cannabis and other hemp products.

Cannabis, in its various forms, has been used for decades recreationally, and medicinally throughout the world.  Recent changes in the legal status of recreational cannabis as well as medical marijuana has meant that more and more individuals are being exposed to its potential allergens.

Currently, there is no reliable blood testing method to test patients for a potential allergy to cannabis.  Without a reliable testing method, many patients who currently have an allergy to cannabis are mis-diagnosed or go undiagnosed.   This is our motivating factor in creating this study, and in developing a reliable test for an allergy to cannabis. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Participating Mayo Clinic locations

More information